Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Sionna Therapeutics, Inc. Common Stock (SION)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SION (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $38.5
1 Year Target Price $38.5
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44.41% | Avg. Invested days 51 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 768.97M USD | Price to earnings Ratio - | 1Y Target Price 38.5 |
Price to earnings Ratio - | 1Y Target Price 38.5 | ||
Volume (30-day avg) 3 | Beta - | 52 Weeks Range 7.25 - 25.19 | Updated Date 08/14/2025 |
52 Weeks Range 7.25 - 25.19 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.5 |
Earnings Date
Report Date 2025-08-11 | When - | Estimate - | Actual -0.4094 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 477933038 | Price to Sales(TTM) - |
Enterprise Value 477933038 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 44092100 | Shares Floating 11223207 |
Shares Outstanding 44092100 | Shares Floating 11223207 | ||
Percent Insiders 7.2 | Percent Institutions 93.43 |
Upturn AI SWOT
Sionna Therapeutics, Inc. Common Stock
Company Overview
History and Background
Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing highly effective and differentiated medicines for cystic fibrosis (CF). Founded in 2019, Sionna is focused on bringing innovation to treat all people living with CF.
Core Business Areas
- CFTR Modulator Development: Focuses on developing small molecule therapeutics that address the underlying cause of CF by modulating the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
Leadership and Structure
Michael P. Grubb is the President and CEO. The company has a board of directors with expertise in drug development and finance.
Top Products and Market Share
Key Offerings
- SION-001: SION-001 is Sionna's lead investigational CFTR potentiator. Being investigated for patients that are not well addressed by other drugs. Competitors are Vertex's Kalydeco, Orkambi, Symdeko, and Trikafta.
Market Dynamics
Industry Overview
The cystic fibrosis therapeutics market is characterized by significant unmet need and growing demand for novel therapies. Vertex Pharmaceuticals currently dominates the market.
Positioning
Sionna Therapeutics aims to differentiate itself by developing CFTR modulators that address the needs of patients who are not adequately treated by existing therapies, aiming for a broader patient population.
Total Addressable Market (TAM)
The global cystic fibrosis market is expected to reach around $13 billion. Sionna aims to capture a significant portion by targeting underserved patient populations.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced leadership team
- Strong investor backing
- Targeting unmet medical need
Weaknesses
- Limited clinical data
- Reliance on a single lead candidate
- Competition from established players
- Early stage company
Opportunities
- Expansion into new CFTR modulator classes
- Partnerships with larger pharmaceutical companies
- Regulatory approval for SION-001
- Growing awareness of CF
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other emerging therapies
- Pricing pressure
Competitors and Market Share
Key Competitors
- VRTX
Competitive Landscape
Sionna is a challenger in a market dominated by Vertex Pharmaceuticals. Sionna's competitive advantage lies in its novel therapeutic approach to treat a broader CF patient base.
Growth Trajectory and Initiatives
Historical Growth: Early-stage growth driven by clinical development progress.
Future Projections: Growth dependent on successful clinical trials and regulatory approval for SION-001.
Recent Initiatives: Advancing SION-001 into Phase 2 clinical trials.
Summary
Sionna Therapeutics is a promising clinical-stage biopharmaceutical company focused on developing novel CFTR modulators for cystic fibrosis. They are targeting patients with CF that are underserved by existing therapies. With a strong cash position and novel approach, the company is well-positioned to advance its lead candidate, SION-001, through clinical trials. However, the company faces competition from established players and risks associated with clinical development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Market research reports
- Company website
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sionna Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2025-02-07 | President, CEO & Director Mr. Michael Cloonan M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 41 | Website https://www.sionnatx.com |
Full time employees 41 | Website https://www.sionnatx.com | ||
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.